Clinical Trial Update: CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of CEND-1 Injection (QLC12102) in advanced metastatic pancreatic ductal adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• CEND-1 Injection (QLC12102)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED